The WACC of Scope Fluidics SA (SCP.WA) is 9.0%.
Range | Selected | |
Cost of equity | 7.7% - 9.2% | 8.45% |
Tax rate | 0.4% - 7.4% | 3.9% |
Cost of debt | 7.0% - 223.1% | 115.05% |
WACC | 7.7% - 10.3% | 9.0% |
Category | Low | High |
Long-term bond rate | 5.5% | 6.0% |
Equity market risk premium | 6.3% | 7.3% |
Adjusted beta | 0.34 | 0.36 |
Additional risk adjustments | 0.0% | 0.5% |
Cost of equity | 7.7% | 9.2% |
Tax rate | 0.4% | 7.4% |
Debt/Equity ratio | 0.01 | 0.01 |
Cost of debt | 7.0% | 223.1% |
After-tax WACC | 7.7% | 10.3% |
Selected WACC | 9.0% | |
Debt/Equity | Unlevered | |||
Peers | Company Name | ratio | Beta | beta |
SCP.WA | Scope Fluidics SA | 0 | 0.06 | 0.06 |
AWM.WA | Airway Medix SA | 0.66 | 0.18 | 0.11 |
BRA.WA | Braster SA w restrukturyzacji | 0.66 | 0 | 0 |
CREO.L | Creo Medical Group PLC | 0.09 | 0.44 | 0.4 |
DIGN.ST | Dignitana AB | 0.05 | -0.55 | -0.53 |
IMMNOV.ST | Immunovia AB (publ) | 0.01 | -0.88 | -0.88 |
INM.WA | Inventionmed SA | 0.09 | 0.48 | 0.44 |
NN6.DE | Nanorepro AG | 0 | 0.05 | 0.05 |
NXTMH.HE | Nexstim Oyj | 0.09 | 0.04 | 0.03 |
SPEC.ST | SpectraCure AB (publ) | 0.07 | -0.99 | -0.93 |
Low | High | |
Unlevered beta | 0.02 | 0.05 |
Relevered beta | 0.01 | 0.04 |
Adjusted relevered beta | 0.34 | 0.36 |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for SCP.WA:
cost_of_equity (8.45%) = risk_free_rate (5.75%) + equity_risk_premium (6.80%) * adjusted_beta (0.34) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.